XML 35 R24.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2022

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Net Income (loss) Per Share

		For the Three Months Ended September 30, (Unaudited)
		2022				2021
Net Income (Loss)		$	(653,150	)		$	(486,558	)
Net income (loss) attributable to common shareholders		$	(653,150	)		$	(486,558	)
Weighted average number of shares of common stock outstanding:
Basic			19,758,520				16,843,045
Diluted			19,758,520				16,843,045
Net income (loss) attributable to common shareholders per share:
Basic		$	(0.03	)		$	(0.03	)
Diluted		$	(0.03	)		$	(0.03	)

		For the Nine Months Ended September 30, (Unaudited)
		2022				2021
Net Income (Loss)		$	(2,175,015	)		$	(2,775,952	)
Net income (loss) attributable to common shareholders		$	(2,175,015	)		$	(2,775,952	)
Weighted average number of shares of common stock outstanding:
Basic			19,736,666				16,805,145
Diluted			19,736,666				16,805,145
Net income (loss) attributable to common shareholders per share:
Basic		$	(0.11	)		$	(0.17	)
Diluted		$	(0.11	)		$	(0.17	)

Schedule of Reconciliation of shares

		For the Three Months Ended September 30, (Unaudited)
		2022				2021
Numerator:
Net Income (Loss)		$	(653,150	)		$	(486,558	)
Denominator:
Basic weighted-average shares			19,758,520				16,843,045
Effect of dilutive securities
Warrants			-				-
Options			-				-
Preferred Stock			-				-
Diluted Weighted Average Shares			19,758,520				16,843,045
Net Income (Loss) Per Common Share:
Basic		$	(0.03	)		$	(0.03	)
Diluted		$	(0.03	)		$	(0.03	)

		For the Nine Months Ended September 30, (Unaudited)
		2022				2021
Numerator:
Net Income (Loss)		$	(2,175,015	)		$	(2,775,952	)
Denominator:
Basic weighted-average shares			19,736,666				16,805,145
Effect of dilutive securities
Warrants			-				-
Options			-				-
Preferred Stock			-				-
Diluted Weighted Average Shares			19,736,066				16,805,145
Net Income (Loss) Per Common Share:
Basic		$	(0.11	)		$	(0.17	)
Diluted		$	(0.11	)		$	(0.17	)

Disaggregation Of Revenue

		For the three months ended September 30, (Unaudited)
		2022				2021
SteraMist Product		$	1,435,000			$	1,657,000
Service and Training			325,000				548,000
Total		$	1,760,000			$	2,205,000

		For the three months ended September 30, (Unaudited)
		2022				2021
United States		$	1,632,000			$	2,028,000
International			128,000				177,000
Total		$	1,760,000			$	2,205,000

		For the nine months ended September 30, (Unaudited)
		2022				2021
SteraMist Product		$	4,448,000			$	4,329,000
Service and Training			1,079,000				1,415,000
Total		$	5,527,000			$	5,744,000

		For the nine months ended September 30, (Unaudited)
		2022				2021
United States		$	4,336,000			$	5,017,000
International			1,191,000				727,000
Total		$	5,527,000			$	5,744,000